Pharma BD Deal Intelligence
A milestone-driven immuno-oncology licensing deal that never delivered: Celgene paid into up to $2.48B in potential milestones for Jounce's JTX-2011 ICOS agonist in solid tumors, but the program stalled well short of its promise, reflected in a critic score in the high 30s.
Jounce Therapeutics announces update on strategic collaboration with Celgene Corporation restructuring the 2016 deal to focus on JTX-8064 macrophage-targeting…
Celgene scraps $2.6B deal and licenses Jounce antibody JTX-8064 in restructured cancer collaboration returning vopratelimab rights to Jounce Therapeutics.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Celgene licensed Jounce Therapeutics' immuno-oncology pipeline including JTX-2011 ICOS agonist antibody, paying $261M upfront with up to $2.48B in milestones.
Vopratelimab (JTX-2011) is an anti-ICOS agonist in Phase 2 (EMERGE, SELECT) in PD-L1+ NSCLC; it competes as a T-cell co-stimulator add-on in a market dominated by checkpoint inhibitors. Anti-PD-(L)1 monotherapy/combo backbone: Keytruda (pembrolizumab, Merck) is 1L SOC monotherapy in PD-L1 TPS ≥50% NSCLC (KEYNOTE-024) and combo with chemo per KEYNOTE-189/407, generating roughly $25B globally; Opdivo + Yervoy (nivolumab + ipilimumab, BMS) approved in CheckMate 9LA; Tecentriq (atezolizumab, Roche) in IMpower150; Libtayo (cemiplimab, Regeneron). T-cell co-stimulation (ICOS, OX40, GITR, 4-1BB): vopratelimab is furthest advanced public ICOS agonist; GSK3359609 feladilimab (GSK) terminated after INDUCE-3 failure; KY1044 (Kymera/Kymab) early phase. The class has been plagued by narrow therapeutic windows and lack of monotherapy signal. Bispecific PD-1/VEGF: ivonescimab (Summit/Akeso) beat pembrolizumab in HARMONi-2 Chinese Phase 3 NSCLC, threatening the anti-PD-1 backbone vopratelimab would pair with. Antibody-drug conjugates: Datroway (datopotamab deruxtecan, Daiichi Sankyo/AstraZeneca) and Rybrevant (amivantamab, J&J) in EGFR NSCLC. Commercial threat is existential: the ICOS class has failed to show monotherapy activity, and vopratelimab requires a predictive biomarker (ICOS-hi CD4 emergence); unless it delivers a strong randomized combo signal with JTX-4014 or pembrolizumab, there is no commercial path.
JTX-4014 is a Phase 1 anti-PD-1 mAb intended as a combination backbone; it enters a fully mature IO checkpoint market where anti-PD-(L)1 scaffolds are commodities and platform differentiation lives in novel targets. Anti-PD-1 mAbs: Keytruda (pembrolizumab, Merck) is the dominant incumbent at roughly $25B in 2023 global sales with over 35 FDA-approved indications; Opdivo (nivolumab, Bristol-Myers Squibb) at roughly $9B; Libtayo (cemiplimab, Regeneron/Sanofi); Tevimbra (tislelizumab, BeiGene/Novartis) FDA-approved 2024 in ESCC. Anti-PD-L1 mAbs: Tecentriq (atezolizumab, Roche), Imfinzi (durvalumab, AstraZeneca) at roughly $4B, Bavencio (avelumab, Merck KGaA/Pfizer). Anti-CTLA-4 combinations: Yervoy (ipilimumab, BMS) remains combo standard; Imjudo (tremelimumab, AstraZeneca) approved in HCC and NSCLC. Novel checkpoints threatening backbone value: LAG-3 (Opdualag, nivolumab+relatlimab, BMS) approved melanoma; TIGIT (tiragolumab Roche) failed Phase 3; PD-1/VEGF bispecific ivonescimab (Summit/Akeso) beat pembrolizumab head-to-head in HARMONi-2 Chinese NSCLC. Commercial threat for any standalone anti-PD-1: Keytruda's tail of patent protection through 2028 in the US and SC formulation approved 2025 extending lifecycle; a non-differentiated backbone like JTX-4014 has essentially no standalone commercial path and only pairs with Jounce's proprietary agonists (ICOS, PD-1xLAG-3).
Celgene paid $261M upfront for JTX-2011 ICOS agonist and broad IO pipeline. Up to $2.48B milestones.
Celgene terminated broad collaboration pre-BMS merger. Retained only JTX-8064; returned vopratelimab rights to Jounce.
Vopratelimab failed Phase 2. JTX-8064 returned by BMS. Jounce ultimately pivoted to different programs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Jounce Therapeutics Inc. (this deal) | 2016 | $2.7B | 29 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
← Browse all deals · How we score deals
More: 2016 deals · Celgene Corporation deals · Oncology deals